These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24904822)

  • 1. Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects.
    Olsen D; Jørgensen JT
    Front Oncol; 2014; 4():105. PubMed ID: 24904822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Companion Diagnostics and Molecular Imaging.
    Puranik AD; Kulkarni HR; Baum RP
    Cancer J; 2015; 21(3):213-7. PubMed ID: 26049701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
    Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
    Front Oncol; 2014; 4():58. PubMed ID: 24744988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Regulation of Companion Diagnostics: A Global Perspective.
    Ansari M
    Ther Innov Regul Sci; 2013 Jul; 47(4):405-415. PubMed ID: 30235516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The current landscape of the FDA approved companion diagnostics.
    Jørgensen JT
    Transl Oncol; 2021 Jun; 14(6):101063. PubMed ID: 33714919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Necessity of strengthening the current clinical regulatory for companion diagnostics: An institutional comparison of the FDA, EMA, and MFDS.
    Kang SL; Woo JH; Kim NH; Kwon JY; Kim SM
    Mol Ther Methods Clin Dev; 2023 Sep; 30():447-458. PubMed ID: 37663648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Companion and complementary diagnostics for infectious diseases.
    Dailey PJ; Elbeik T; Holodniy M
    Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Missing Companion Diagnostic for US Food and Drug Administration-Approved Hematological and Oncological Drugs.
    Jørgensen JT
    JCO Precis Oncol; 2022 Jun; 6():e2200100. PubMed ID: 35709402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Companion Diagnostics: State of the Art and New Regulations.
    Valla V; Alzabin S; Koukoura A; Lewis A; Nielsen AA; Vassiliadis E
    Biomark Insights; 2021; 16():11772719211047763. PubMed ID: 34658618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncology drug-companion diagnostic combinations.
    Jørgensen JT
    Cancer Treat Res Commun; 2021; 29():100492. PubMed ID: 34844911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
    Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
    Front Genet; 2015; 6():357. PubMed ID: 26858745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-Development of Oncology Drugs and Companion Diagnostics: Analyses of Approval Lags and Drug Development Periods in Recently Approved Cases in Japan.
    Tanaka A; Suzuki H; Toyoshima S; Nagai N
    Ther Innov Regul Sci; 2022 Jan; 56(1):85-95. PubMed ID: 34406635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twenty-five years with companion diagnostics.
    Jørgensen JT
    Chin Clin Oncol; 2023 Dec; 12(6):65. PubMed ID: 37953243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
    Cowling T; Boucher M
    Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency.
    Maliepaard M; Nibi P; Nibi G; Pasmooij AMG
    Front Med (Lausanne); 2022; 9():893028. PubMed ID: 35602486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Database Approach to Identify Companion Diagnostic Testing in Clinical Trials under the New In Vitro Diagnostic Medical Devices Regulation.
    Wollenhaupt C; Sudhop T; Knoess W
    Diagnostics (Basel); 2023 Jun; 13(12):. PubMed ID: 37370933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein array-based companion diagnostics in precision medicine.
    Poulsen TBG; Karamehmedovic A; Aboo C; Jørgensen MM; Yu X; Fang X; Blackburn JM; Nielsen CH; Kragstrup TW; Stensballe A
    Expert Rev Mol Diagn; 2020 Dec; 20(12):1183-1198. PubMed ID: 33315478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming regulatory challenges in the development of companion diagnostics for monitoring and safety.
    Shimazawa R; Ikeda M
    Per Med; 2016 Mar; 13(2):155-167. PubMed ID: 29749900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.